Pharmaceutical Risk-Sharing Agreements

被引:0
|
作者
Joseph P. Cook
John A. Vernon
Richard Manning
机构
[1] NERA Economic Consulting,Department of Finance
[2] The University of Connecticut,undefined
[3] Department of Economic Policy,undefined
[4] Pfizer Inc.,undefined
[5] The University of Connecticut,undefined
来源
PharmacoEconomics | 2008年 / 26卷
关键词
Bortezomib; Fair Trading; Pharmaceutical Expenditure; Branded Drug; Valuable Innovation;
D O I
暂无
中图分类号
学科分类号
摘要
Increased spending on pharmaceuticals continues to foster debate over healthcare policy. The increasing costs of bringing products to the market, as well as increased utilization of pharmaceuticals contribute to increased pharmaceutical expenditure; however, appropriate pharmaceutical use can, in certain cases, reduce overall healthcare costs. Nevertheless, the perception of high drug prices still puts pressure on pharmaceutical companies to build confidence in the proposition that their products are worth the additional expense. One potential approach to building this confidence, and maintaining investment incentives, is for the pharmaceutical company to share the risk of a situation in which there is uncertainty about whether the product is effective for the consumer and payer. Such risk-sharing arrangements for pharmaceuticals, like warranties, can be used to signal high quality when product quality is not fully observable. While there may be difficulties in devising such schemes for every product, such risk-sharing plans may become a staple feature of the market in the future.
引用
收藏
页码:551 / 556
页数:5
相关论文
共 50 条
  • [21] Risk-sharing agreements to cover environmental damage: theory and practice
    Liu, Jing
    Faure, Michael
    INTERNATIONAL ENVIRONMENTAL AGREEMENTS-POLITICS LAW AND ECONOMICS, 2018, 18 (02) : 255 - 273
  • [22] Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia
    Reyes-Trave, Anna
    Guarga-Sole, Laura
    Roig-Izquierdo, Marta
    Alonso-Perez, Enrique
    Clopes-Estela, Ana
    Delgadillo-Duarte, Joaquin
    PHARMACOECONOMICS, 2021, 39 (09) : 973 - 982
  • [23] Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia
    Anna Reyes-Travé
    Laura Guarga-Solé
    Marta Roig-Izquierdo
    Enrique Alonso-Pérez
    Ana Clopés-Estela
    Joaquín Delgadillo-Duarte
    PharmacoEconomics, 2021, 39 : 973 - 982
  • [24] PHARMACEUTICAL PRICING UNDER UNCERTAINTY: RISK-SHARING CONTRACTS
    Rodriguez-Ibeas, R.
    Arizti, I
    Antonanzas, F.
    VALUE IN HEALTH, 2011, 14 (07) : A360 - A360
  • [25] THE IMPACT OF RISK-SHARING AGREEMENTS ON DRUG REIMBURSEMENT DECISIONS IN SOUTH KOREA
    Choi, M. H.
    Ghosh, W.
    Brooks-Rooney, C.
    VALUE IN HEALTH, 2018, 21 : S57 - S57
  • [26] Risk-sharing agreements for innovative drugsA new solution to old problems?
    Gérard de Pouvourville
    The European Journal of Health Economics, 2006, 7 (3) : 155 - 157
  • [27] MAJOR TRENDS AND IMPLEMENTATION OF RISK-SHARING AGREEMENTS IN CHINA: A SYSTEMATIC REVIEW
    Lou, S.
    Xing, Y.
    Wu, Y.
    Wu, M.
    Wang, R.
    Jiang, B.
    Xiong, T.
    VALUE IN HEALTH, 2020, 23 : S299 - S299
  • [28] GLOBAL PHARMACEUTICAL RISK-SHARING AGREEMENT TRENDS IN 2010 AND 2011
    Ando, G.
    Reinaud, F.
    Bharath, A.
    VALUE IN HEALTH, 2011, 14 (07) : A360 - A360
  • [29] THE POSSIBILITY OF INITIATING TRUE RISK-SHARING AGREEMENTS IN THE CURRENT ECONOMIC SITUATION
    Germanenko, A.
    Traulsen, J. M.
    VALUE IN HEALTH, 2014, 17 (07) : A449 - A449
  • [30] AVAILABILITY OF RISK SHARING AGREEMENTS IN THE TURKISH PHARMACEUTICAL SECTOR
    Tuna, E.
    Tatar, M.
    Ergin, G.
    Senturk, A.
    Atikeler, K.
    VALUE IN HEALTH, 2014, 17 (07) : A415 - A415